What is GHRP-6?
GHRP-6 stands for Growth Hormone-Releasing Peptide 6. It is a synthetic, six-amino-acid peptide — a tiny chain of protein building blocks — designed to trigger the release of growth hormone (GH) from the pituitary gland, the pea-sized gland at the base of the brain. It belongs to a family called GH secretagogues, meaning compounds that tell the body to secrete GH. Researchers also know it by its full nickname: growth hormone-releasing hexapeptide-6.
One feature that makes GHRP-6 stand out from similar peptides is its strong ability to stimulate appetite. That side effect — and the biological pathway behind it — has made it a useful research tool for scientists studying hunger, metabolism, heart protection, and kidney repair, among other areas. It is a research compound only, not approved for human clinical use.
How GHRP-6 Works
Think of the growth hormone secretagogue receptor (called GHSR-1α) as a locked door on certain cells. GHRP-6 acts like a key that fits that lock. When GHRP-6 binds to GHSR-1α on pituitary cells, it kicks off a chain of internal signals — including activating an enzyme called PKCδ (protein kinase C delta) — that ultimately phosphorylates a protein called CREB, which then instructs the cell to release growth hormone.[5]
GHRP-6 also amplifies the effect of the body's natural GH-releasing hormone (GHRH). When researchers give both GHRP-6 and GHRH together, the GH spike is larger than either would produce alone.[5] Scientists use this synergy deliberately in diagnostic testing.[1]
Separately, a closely related molecule called [D-Lys3]-GHRP-6 is used in research as a blocker of GHSR-1α — essentially a key that jams the lock — helping researchers figure out which effects in an experiment are genuinely caused by that receptor pathway.[4]
What the Research Shows
GH Deficiency Diagnosis
Two 1996 clinical studies looked at whether an intravenous dose of GHRP-6 could reliably identify children and adults whose pituitary glands don't make enough GH. The results were mixed for general GH deficiency screening — there was too much overlap between sick and healthy groups — but the combined GHRH + GHRP-6 test showed a near-complete shutdown of GH response in patients with pituitary stalk transection (physical damage to the pituitary's connection to the brain), suggesting a potential diagnostic use for that specific condition.[1][6] Researchers also noted that GH responses to GHRP-6 were more consistent across different patients than responses to GHRH alone.[6]
Heart Protection
Doxorubicin is a powerful chemotherapy drug — but it can seriously damage the heart over time, causing a condition called dilated cardiomyopathy (where the heart muscle weakens and the chambers stretch out). In a 2024 preclinical rat study, GHRP-6 given alongside doxorubicin prevented the loss of heart muscle fibers and the dangerous dilation of the left ventricle. It also reduced damage to other organs. The researchers found GHRP-6 worked by boosting cellular antioxidant defenses, turning up a pro-survival gene called Bcl-2, and keeping the mitochondria (the cell's power stations) intact.[2]
Kidney Injury
A 2025 study took a creative approach: scientists built a self-assembling GHRP-6 hydrogel — essentially a gel made from the peptide itself — and applied it in a mouse model of acute kidney injury (AKI). The hydrogel appeared to reprogram how kidney tubule cells handled their energy and metabolism, boosting key molecules involved in amino acid and fatty acid processing. It also activated a growth-and-survival signaling pathway called mTOR-P70, helping fragile kidney cells survive in a low-oxygen environment.[3]
Muscle Biology
Research on [D-Lys3]-GHRP-6 — the receptor-blocking cousin of GHRP-6 — found that it activated autophagy in skeletal muscle. Autophagy is the cell's self-cleaning process, where it breaks down and recycles damaged components. This effect appeared to work through a different receptor (CXCR4), not GHSR-1α, highlighting that GHRP-6-family peptides can influence cells through more than one pathway.[4]
What GHRP-6 Is Being Studied For
- Diagnosing GH deficiency — especially pituitary stalk damage — in clinical research settings[1]
- Cardioprotection — shielding the heart from chemotherapy-related damage[2]
- Acute kidney injury recovery — via metabolic reprogramming of kidney cells[3]
- Understanding hunger and metabolism — because GHRP-6 strongly stimulates appetite through GHSR-1α, it is a useful tool for studying the ghrelin system
- Receptor pharmacology — [D-Lys3]-GHRP-6 is widely used as a ghrelin receptor blocker in preclinical experiments[4]
- Anti-doping science — detection methods have been studied after nasal administration
How GHRP-6 Is Dosed in Research
Doses in published studies vary widely depending on the research goal, the model used (human, rat, or mouse), and the route of administration (intravenous, intraperitoneal, or nasal). For example, diagnostic GH-stimulation protocols have used single intravenous doses as small as 1 mcg, while cardioprotection experiments in rats have used much larger amounts, and anti-doping detection work has involved nasal administration at the milligram level. Because context matters enormously, always check the specific protocol. See the dosage chart on this page for a full breakdown of doses from published research, and use the calculator to reference amounts for your own research planning.
Mixing and Storing GHRP-6
GHRP-6 typically arrives as a lyophilized powder — that just means freeze-dried. To prepare it for use, researchers add a small amount of sterile bacteriostatic water (water with a tiny amount of benzyl alcohol that prevents bacterial growth) or sterile water directly to the vial. This is called reconstitution. Swirl the vial gently — don't shake it hard, as vigorous agitation can damage the peptide chain. Once mixed, the solution should be stored in a refrigerator (around 2–8 °C / 36–46 °F) and used within a reasonable window, typically a few weeks. Keep unmixed powder away from heat, light, and moisture, ideally in a freezer for longer-term storage. Always label vials with the date of reconstitution. These are general handling guidelines; always follow the specific storage instructions provided with your research-grade material.
Sources
- Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. — Journal of pediatric endocrinology & metabolism : JPEM, 1996. PMID 8887178.
- Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. — Frontiers in pharmacology, 2024. PMID 38873418.
- Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. — Journal of nanobiotechnology, 2025. PMID 41327290.
- [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle. — Molecular and cellular endocrinology, 2015. PMID 25450862.
- GHRP-6 induces CREB phosphorylation and growth hormone secretion via a protein kinase Csigma-dependent pathway in GH3 cells. — Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2010. PMID 20407870.
- Evaluation of pituitary GH reserve with GHRP-6. — Journal of pediatric endocrinology & metabolism : JPEM, 1996. PMID 8887173.
EN
BR
ES
FR